Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), retaining the price target of ...

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price ...

Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, ...

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.

Novartis (NVS) acquires gene therapy developer Kate Therapeutics for up to $1.1B, expanding expertise in neuromuscular diseases. Read more here.

In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phas ...

Dundee University spin-out Exscientia has been taken over by US pharmaceutical rival Recursion, in a deal worth around £500m. The firm was delisted from the NASDAQ stock exchange on Wednesday after ...

However, despite the company’s apparent clinical success, Amgen’s stock fell approximately 11% during trading ... while ...